Rezolute says FDA recommends pre-BLA meeting for ersodetug in congenital hyperinsulinism

By Public Technologies
  • Rezolute received an FDA recommendation to hold a Type B pre-BLA meeting ahead of a potential filing for ersodetug in congenital hyperinsulinism.
  • The Phase 3 sunRIZE study showed glycemic improvement, but missed its primary endpoint, limiting the strength of the main efficacy claim.
  • FDA reviewed extensive continuous glucose monitoring analyses, then urged a pre-BLA discussion without taking a position on approvability.
  • Topline Phase 3 upLIFT results in tumor-related hyperinsulinism are expected this quarter, shaping the broader BLA submission strategy.
  • An open-label extension remains ongoing, supporting longer-term treatment experience and potential durability of benefit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050700PRIMZONEFULLFEED9839272) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.